~~<i id='EB88B6A010'><strike id='EB88B6A010'><tt id='EB88B6A010'><pre id='EB88B6A010'></pre></tt></strike></i>~~

Home» explore» comprehensive

comprehensive

author：explore 2025-09-30 10:46:53 Page View：73

Editor’s note: A recording of the event is embedded below.

After a few go-go years, the early-stage biotech market has cooled considerably. Two VCs will weigh in on what distinguishes great science from bad investments.

Featured Speakers

Irena Melnikova, Ph.D., partner, Pfizer Ventures
Rakhshita Dhar, senior director, venture investments, Leaps by Bayer
Frank S. David, M.D., Ph.D., managing director, Pharmagellan (moderator)

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： The high cost of giving birth even with insurance
Next article： The Supreme Court will review a ruling striking down a domestic violence federal gun ban

focus

Medicare details structure of new drug price negotiation program

MedicareonFridayreleasednewdetailsabouthowitsnewdrugpricenegotiationprogramwillwork,justtwomonthsbef

United colonoscopy coverage change 'may cost lives,' doctors say

AdobeWhengastroenterologistslearnedinMarchthatUnitedHealthcareplanstobarricademanycolonoscopiesbehin

Peter Hotez and the public health issue of online harassment

AdobeFather’sDayweekendwasanythingbutcalmonTwitter,whicheruptedasvaccineexpertPeterHotezwaschallenge

Ring Therapeutics, a Flagship gene therapy startup, lays off 20% of staff

AdobeRingTherapeutics,agenetherapystartuplaunchedbyFlagshipPioneering,haslaidoffjustunder20%ofitssta